Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05770661
Recruiting Observational

China Children Eye Study

NCT05770661 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Eye Disease Prevention and Treatment Center
Phase
Observational
Started
2023-03-10
Last updated
2026-08-07

Condition(s) studied

Axial LengthMyopiaChild Development

Study summary

The primary objective of this multi-center, observational study is to establish the reference ranges of axial length in Chinese children and adolescents.

30,000 children aged 3-18 years were examined with cycloplegia to collect their ocular parameters and were all followed up for three years with annual visits.

Eligibility

Sex
ALL
Min age
3 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Aged 3 to 18 years * Have been lived in the research areas for at least one year, and will not move to other places in the following two years * Parents or guardians sign an informed consent form, and children over 6 years old need oral consent to participate Exclusion Criteria: * Mental diseases, unable to cooperate to complete the eye assessment * Ophthalmic diseases, inability to cooperate to complete the inspection

Primary outcome measure(s)

  • Axial length — 2023-2026
    Axial length in millimeter was examined by IOL Master

Trial sites (2)

FacilityCityRegionStatus
Shanghai Eye Disease Prevention & Treatment Center Shanghai Shanghai Municipality Recruiting
Shanghai Eye Disease Prevention and Treatment Center Shanghai China Recruiting

More Shanghai Eye Disease Prevention and Treatment Center trials in China

School-based Myopia Control Trial for Children With Premyopia or Myopia Recruiting
Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses Enrolling by invitation
Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control Active, not recruiting
LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia Recruiting
Managing Premyopia in Chinese Children Using Artificial Intelligence Assisted Defocus Incorporated Multiple Segments Based Spectacle Lens: a Randomized Controlled Clinical Trial Recruiting

Other trials for the same condition

A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops Active, not recruiting
Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control Active, not recruiting
Auricular Acupressure Reduces Rebound Effects After Discontinuation of Atropine Starting soon
Spectacle Films Utilising S.T.O.P.® Technology for Slowing Down Myopia Progression in Children Active, not recruiting
Efficacy and Influencing Factors of Repeated Low-level Red-light in Myopia Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05770661 on ClinicalTrials.gov ↗ ← All trials in China